Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

CAMBRIDGE, MA / ACCESS Newswire / January 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats CAMBRIDGE, MA / ACCESS ...

Following four straight sessions of gains, Moderna (NASDAQ ... 17 European countries will have access to the Cambridge, MA-based biotech's messenger RNA-based shot for up to four years.

The company is among dozens spun out by Flagship Pioneering, an American venture-capital firm which also incubated Moderna ... “We’re bringing Cambridge MA to Cambridge UK,” says Jake ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...